Physician profile
Jared Bratvold
NPI 1609076058
$6,722.23
in general payments reported to CMS, 2019-2025
29 companies · $1,600 in 2025
The $1,600 reported for 2025 was more than what 79% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,491 · 2020: $168 · 2021: $54.21 · 2022: $433 · 2023: $638 · 2024: $339 · 2025: $1,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,520 · Food and Beverage: $1,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,520.00 |
| Food and Beverage | $1,056.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,738.78 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $222.38 | 2023-2024 | Gattex, Eohilia |
| Medtronic, INC. | $195.41 | 2022-2024 | Sonicision, Ligasure |
| Acera Surgical, INC. | $187.06 | 2019-2024 | Restrata Wound Matrix |
| Csl Behring | $179.06 | 2021-2023 | Kcentra |
| Smith+Nephew, INC. | $161.12 | 2023-2024 | Grafix Pl, Collagenase Santyl, Stravix Pl |
| W. L. Gore & Associates, INC. | $99.40 | 2020-2024 | Gore Synecor Biomaterial |
| Astrazeneca Pharmaceuticals LP | $92.75 | 2023 | Andexxa |
| Alexion Pharmaceuticals, INC. | $92.27 | 2022 | |
| Abbvie INC. | $87.85 | 2021-2023 | Dalvance |
| Kerecis Limited | $77.46 | 2022-2025 | Kerecis Omega3 Surgiclose, Kerecis Surgiclose, Kerecis Omega3 Graftguide |
| Teleflex LLC | $73.77 | 2019 | |
| Kci USA, INC. | $73.74 | 2019-2023 | Activ.A.C., V.A.C. Veraflo |
| Misonix INC | $57.39 | 2019 | |
| Portola Pharmaceuticals, LLC | $51.00 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanos Medical | $49.18 | 2019 | |
| Tela Bio, INC. | $47.68 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Allergan, INC. | $29.20 | 2019-2020 | |
| Cumberland Pharmaceuticals, INC. | $26.93 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $24.60 | 2023 | Exparel |
| Davol INC. | $21.98 | 2022 | |
| Hologic Sales and Service, LLC | $19.64 | 2025 | Aptima |
| Acell, INC. | $19.37 | 2020 | |
| Boston Scientific Corporation | $17.94 | 2019 | |
| Convatec INC. | $17.68 | 2023 | |
| Merck Sharp & Dohme LLC | $16.85 | 2019 | |
| Z-Medica, LLC | $15.81 | 2019 | |
| Sanara Medtech INC. | $13.65 | 2024 | Celleraterx |
| Integra Lifesciences Corporation | $12.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Bratvold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.